[1] Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[2] Torre L A, Trabert B, DeSantis C E, et al. Ovarian cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68:284-296.
[3] Tew W P, Lacchetti C, Kohn E C. Poly(ADP-Ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update[J]. J Clin Oncol, 2022, 40(33): 3878-3881.
[4] Gaillard S, Duska L, Broadwater G, et al. AdoRN trial: atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly-diagnosed advanced-stage epithelial ovarian cancer[J]. Gynecol Oncol, 2021, 162:S61.
[5] Coquard I L, Savoye A M, Schiffler C, et al. Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial[J]. Nat Commun, 2024, 15:5931.
[6] Park J, Lee J B, Lim M C, et al. Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: Primary analysis in the original cohort of KGOG3046/TRU-D[J]. J Immunother Cancer, 2023, 11(10):e007444.
[7] How J A, Dang M, Lee S, et al. Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: clinical and translational results from a phase 2 trial[J]. Medicine, 2025, 6(1):100494.
[8] Monk B J, Colombo N, Oza A M, et al. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer(JAVELIN Ovarian 100): an openlabel, randomised, phase 3 trial[J]. Lancet Oncol, 2021, 22(9):1275-1289.
[9] Eskander R N, Ledermann J A, Birrer M J, et al. JAVELIN ovarian PARP 100 study design: Phase Ⅲ trial of avelumab+chemotherapy followed by avelumab+talazoparib maintenance in previously untreated epithelial ovarian cancer[J]. J Clin Oncol, 2019, 37(Suppl 8):S9.
[10] Monk B J, Oaknin A, O'Malley D M, et al. LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib(RUCA) + nivolumab(NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients(pts) with newly diagnosed ovarian cancer(OC)[J]. Ann Oncol, 2024, 35:S1223-S1224.
[11] Pignata S, Bookman M, Sehouli J, et al. Overall survival and patient-reported outcome results from the placebo controlled randomized phase Ⅲ IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage Ⅲ/Ⅳ ovarian cancer[J]. Gynecol Oncol, 2023, 177: 20-31.
[12] Harter P, Wimberger P, Okamoto A, et al. Durvalumab plus paclitaxel/carboplatin plus bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance among patients with newly-diagnosed advanced ovarian cancer without a tumor BRCA1/BRCA2 mutation: updated results from DUO-O/ENGOT-OV46/GOG-3025 trial[J]. Gynecol Oncol, 2024,190:S65-S66.
[13] Colombo I, Karakasis K, Suku S, et al. Chasing immune checkpoint inhibitors in ovarian cancer: novel combinations and biomarker discovery[J]. Cancers(Basel),2023,15(12):3220.
[14] Drew Y, Kim J W, Penson R T, et al. Olaparib plus durvalumab, with or without bevacizumab, as treatment in PARP inhibitor-naive platinum-sensitive relapsed ovarian cancer: a phase II multi-cohort study[J]. Clin Cancer Res,2024,30(1):50-62.
[15] Kim Y N, Park B, Kim J W, et al. Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4[J]. Nat Commun,2023,14(1):5476.
[16] Kurtz J E, Pujade L E, Oaknin A, et al. Atezolizumab combined with bevacizumab and platinumbased therapy for platinum-sensitive ovarian cancer: placebocontrolled randomized phase Ⅲ ATALANTE/ENGOT-ov29 trial[J]. J Clin Oncol, 2023, 41(30): 4768-4778.
[17] Drew Y, Kim J W, Penson R T, et al. Maintenance niraparib for recurrent ovarian cancer with a platinum-free interval >6 months: ENGOT-OV41/GEICO 69-O/ANITA phase III trial[J]. J Clin Oncol, 2024, 42(36):4294-4304.
[18] Varga A, Piha P S, Ott P A, et al. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028[J]. Gynecol Oncol,2019,152(2):243-250.
[19] Matulonis U A, Shapira-Frommer R, Santin A D, et al. Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer[J]. J Clin Oncol, 2020, 38(15suppl):6005.
[20] Hamanishi J, Takeshima N, Katsumata N, et al. Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan(NINJA)[J]. J Clin Oncol, 2021, 39(33):3671-3681.
[21] Kristeleit R, Clamp A R, Gourley C, et a. Efficacy of pembrolizumab monotherapy(PM) for advanced clear cell gynaecological cancer(CCGC): phase Ⅱ PEACOCC trial[J]. Ann Oncol, 2022, 33:S783.
[22] Zamarin D, Burger R A, Sill M W, et al. Randomized phase Ⅱ trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study[J]. J Clin Oncol, 2020, 38(16):1814-1823.
[23] Hinchcliff E, Patel A, Fellman B, et al. Randomized phase II trial of durvalumab(anti-PDL1) and tremelimumab(anti-CTLA4) administered in combination versus sequentially for the treatment of recurrent platinum-resistant non-clear cell ovarian cancer(NCT03026062)[J]. Gynecol Oncol, 2021, 162:S39.
[24] Lee E K, Xiong N, Cheng S C, et al. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: a phase 2 clinical trial[J]. Gynecol Oncol, 2020, 159:72-78.
[25] O'cearbhaill R E, Homicsko K, Wolfer A, et al. A phase Ⅰ/Ⅱ study of chemoimmunotherapy with durvalumab(durva) and pegylated liposomal doxorubicin(PLD) in platinum-resistant recurrent ovarian cancer(PROC): genomic sequencing and updated efficacy results[J]. Gynecol Oncol, 2020, 159(Suppl 1):41.
[26] Walsh C S, Kamrava M, Rogatko A, et al. Phase Ⅱ trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer[J]. PLoS One, 2021, 16(6):e0252665.
[27] Pujade L E, Fujiwara K, Ledermann J A, et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer(JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study[J]. Lancet Oncol, 2021, 22(7):1034-1046.
[28] Kim S I, Joung J G, Kim Y N, et al. Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer(KGOG 3045): a phase II umbrella trial[J]. Gynecol Oncol, 2024, 182:7-14.
[29] Konstantinopoulos P A, Waggoner S, Vidal G A, et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma[J]. JAMA Oncol, 2019, 5(8):1141-1149.
[30] Lampert E J, Zimmer A, Padget M, et al. Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study[J]. Clin Cancer Res, 2020, 26(16):4268-4279.
[31] Randall L M, O'Malley D M, Monk B J, et al. Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a phase II study(MOONSTONE/GOG-3032)[J]. Gynecol Oncol, 2023, 178:161-169.
[32] Moroney J W, Powderly J, Lieu C H, et al. Safety and clinical activity of atezolizumab plus bevacizumab in patients with ovarian cancer: a phase Ⅰb study[J]. Clin Cancer Res, 2020, 26(21):5631-5637.
[33] Liu J F, Herold C, Gray K P, et al. Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: a phase 2 clinical trial[J]. JAMA Oncol, 2019, 5(12):1731-1738.
[34] Peng Z, Li H, Gao Y, et al. Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma(INOVA): a multicentre, single-arm, phase 2 trial[J]. Lancet Oncol, 2024, 25(10):1288-1297.
[35] González-Martín A, Chung H C, Saada-Bouzid E, et al. Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: results from the phase 2 multicohort LEAP-005 study[J]. Gynecol Oncol, 2024, 186:182-190.
[36] Lan C Y, Zhao J, Yang F, et al. Anlotinib combined with TQB2450 in patients with platinum-resistant or refractory ovarian cancer: a multi-center, single-arm, phase 1b trial[J]. Cell Rep Med, 2022, 3(7):100689.
[37] Xia L, Peng J, Lou G, et al. Antitumor activity and safety of camrelizumab plus famitinib in patients with platinumresistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study[J]. J Immunother Cancer, 2022, 10(1):e003831.
[38] Zsiros E, Lynam S, Attwood K M, et al. Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: a phase 2 nonrandomized clinical trial[J]. JAMA Oncol, 2021, 7(1):78-85.
[39] Philipp H,Patricia P, Els V N, et al. Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer: a randomized phase Ⅲ trial(AGO-OVAR 2.29/ENGOT-ov34)[J]. Int J Gynecol Cancer, 2020, 30(12):1997-2001.
[40] Liu J F, Gaillard S, Hendrickson Andrea E W, et al. Niraparib, dostarlimab, and bevacizumab as combination therapy in pretreated, advanced platinum-resistant ovarian cancer: findings from cohort A of the OPAL phase II trial[J]. JCO Precis Oncol, 2024, 8:e2300693.
[41] Freyer G, Floquet A, Tredan O, et al. Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group[J]. Nat Commun, 2024, 15: 1985.
[42] Lee J M. Randomized phase Ⅱ trial of durvalumab in combination with olaparib and cediranib(DOC) compared to olaparib and cediranib(OC) or durvalumab and cediranib(DC) or standard of care chemotherapy(SOC) in platinum-resistant ovarian cancer with prior bevacizumab(NRG-GY023)[J]. Ann Oncol, 2023, 34: S511.
[43] Colombo I, Karakasis K, Suku S,et al.Chasing immune checkpoint inhibitors in ovarian cancer: novel combinations and biomarker discovery[J].Cancers(Basel), 2023,15(12):3220.
[44] Landen C N, Molinero L, Hamidi H, et al. Influence of genomic landscape on cancer immunotherapy for newly diagnosed ovarian cancer: biomarker analyses from the IMagyn050 randomized clinical trial[J]. Clin Cancer Res, 2023, 29(9):1698-1707.
[45] Duaa H A,Nicole R,Claire F F. The search for genomic biomarkers of response to immunotherapy in ovarian cancer[J]. Clin Cancer Res, 2023, 29(9):1645-1647.